CITHEFOR, Université de Lorraine, F-54000 Nancy, France.
Department of Pharmacology and Toxicology, MHeNS-School for Mental Health and Neuroscience, Maastricht University, 6200 MD Maastricht, The Netherlands.
Molecules. 2023 Jul 18;28(14):5481. doi: 10.3390/molecules28145481.
The AT receptor has mainly been associated with the pathological effects of the renin-angiotensin system (RAS) (e.g., hypertension, heart and kidney diseases), and constitutes a major therapeutic target. In contrast, the AT receptor is presented as the protective arm of this RAS, and its targeting via specific agonists is mainly used to counteract the effects of the AT receptor. The discovery of a local RAS has highlighted the importance of the balance between AT/AT receptors at the tissue level. Disruption of this balance is suggested to be detrimental. The fine tuning of this balance is not limited to the regulation of the level of expression of these two receptors. Other mechanisms still largely unexplored, such as -nitrosation of the AT receptor, homo- and heterodimerization, and the use of AT receptor-biased agonists, may significantly contribute to and/or interfere with the settings of this AT/AT equilibrium. This review will detail, through several examples (the brain, wound healing, and the cellular cycle), the importance of the functional balance between AT and AT receptors, and how new molecular pharmacological approaches may act on its regulation to open up new therapeutic perspectives.
血管紧张素受体主要与肾素-血管紧张素系统 (RAS) 的病理效应相关(例如高血压、心脏和肾脏疾病),是主要的治疗靶点。相比之下,血管紧张素受体被认为是 RAS 的保护臂,通过特定激动剂靶向该受体主要用于抵消血管紧张素受体的作用。局部 RAS 的发现强调了组织水平上血管紧张素/血管紧张素受体之间平衡的重要性。这种平衡的破坏被认为是有害的。这种平衡的微调不仅限于这两种受体表达水平的调节。其他机制(如血管紧张素受体的亚硝基化、同型和异型二聚化以及使用血管紧张素受体偏向激动剂)仍在很大程度上未被探索,这些机制可能对该血管紧张素/血管紧张素平衡的设定有显著贡献和/或干扰。本文将通过几个例子(大脑、伤口愈合和细胞周期)详细阐述血管紧张素和血管紧张素受体之间功能平衡的重要性,以及新的分子药理学方法如何作用于其调节以开辟新的治疗前景。